Half-year report · Q2
3055.TEDINET S100UNC6
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥141.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥275.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥135.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥884m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥730m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥884m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥730m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥149.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥147.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥147.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥88.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥86.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥60.8bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥60.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥20.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥696m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥898m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥596m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥41.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.2 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.35 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.6% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥33m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Otherother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥566m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥5m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥289m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥712m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥22m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.1bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.8bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥309m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥407m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥142m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥102.8bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.6bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥750m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥147.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥141.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| Otherother segments | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥29m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Otherother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥615m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥27m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥794m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥263m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥530m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥33m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥31.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥31.4bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥283m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥581m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥106m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥100.0bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥95.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥502m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥142.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥135.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 541
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Basic policy regarding control of company (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)札幌証券取引所 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)有限会社いつわ企画 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)札幌市中央区北６条西16丁目１番地５ | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)有限会社タスク企画 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)札幌市北区あいの里３条７丁目１－11 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)株式会社アステム | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)大分市西大道２丁目３番８号 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社北海道銀行 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)札幌市中央区大通西４丁目１番地 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)株式会社北洋銀行 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)札幌市中央区大通西３丁目７番地 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)ほくたけ従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)札幌市中央区北６条西16丁目１番地５ | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)エーザイ株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |